Sareum Hldgs Plc Asset Resilience Ratio
Sareum Hldgs Plc asset resilience ratio. Sareum Hldgs Plc (SAR) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sareum Hldgs Plc (SAR) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sareum Hldgs Plc (2014–2021)
Asset resilience ratio of Sareum Hldgs Plc from 2014 to 2021. This chart shows how Sareum Hldgs Plc's Asset Resilience Ratio has changed over time. Read Sareum Hldgs Plc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sareum Hldgs Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SAR asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.00 | 0.0% |
| Total Liquid Assets | GBX1.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sareum Hldgs Plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sareum Hldgs Plc Industry Peers by Asset Resilience Ratio
Compare Sareum Hldgs Plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Sareum Hldgs Plc Asset Resilience Ratio by Year (2014–2021)
Sareum Hldgs Plc asset resilience ratio by year from 2014 to 2021. The table below shows the annual Asset Resilience Ratio data for Sareum Hldgs Plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 87.24% | GBX2.69 Million ≈ $326.83 |
GBX3.08 Million ≈ $374.65 |
-2.39pp |
| 2020-06-30 | 89.63% | GBX1.79 Million ≈ $218.34 |
GBX2.00 Million ≈ $243.60 |
+89.63pp |
| 2019-06-30 | 0.00% | GBX1.00 ≈ $0.00 |
GBX1.24 Million ≈ $151.01 |
-75.37pp |
| 2018-06-30 | 75.37% | GBX1.37 Million ≈ $166.53 |
GBX1.82 Million ≈ $220.96 |
-16.45pp |
| 2017-06-30 | 91.82% | GBX2.30 Million ≈ $279.41 |
GBX2.50 Million ≈ $304.32 |
+80.63pp |
| 2014-06-30 | 11.18% | GBX200.00K ≈ $24.33 |
GBX1.79 Million ≈ $217.58 |
-- |
About Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more